Mendus AB (CHIX:IMMUS) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 06, 2026)


CHIX:IMMUS Mendus AB CHIX:IMMUS
27 GF Score
Price kr32.70
! 2 Warning Signs
View Full Analysis

What is Mendus AB Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Mendus AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

CHIX:IMMUS vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Mendus AB's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mendus AB Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mendus AB's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Mendus AB's Margin of Safety % (DCF FCF Based) falls into.


CHIX:IMMUS
27GF Score
Mendus AB CHIX:IMMUS
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Business Description

Other Exchanges IMMU:Sweden1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
27GF Score

Get the complete analysis for CHIX:IMMUS

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr32.70
Price